GlobeNewswire Inc.··NaCocrystal Pharma Advances Norovirus Program as Cash Runway Tightens
Cocrystal completes Phase 1b enrollment for norovirus drug CDI-988, gains FDA Fast Track designation and NIH grant, but faces cash constraints with $4.7M on hand.
COCPclinical developmentantiviral